UCB S.A.: Psoriasis trials

The registry lists 25 Psoriasis studies with UCB S.A. as lead sponsor. 1 are open to participants now and 20 have results posted.

Phase 1 3Phase 2 8Phase 3 14No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisRecruitingNCT07219420Phase 3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT06011733Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05020249Phase 3Results posted
• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04718896Phase 2Results posted
• A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)CompletedNCT04163016Phase 1Results posted
• A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)CompletedNCT03766685Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03598790Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03536884Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03412747Phase 3Results posted
• A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03410992Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03370133Phase 3Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque PsoriasisCompletedNCT03230292Phase 2Results posted
• A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisCompletedNCT03051217Phase 2/3Results posted
• A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03025542Phase 2Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03010527Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT02905006Phase 2Results posted
• Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)CompletedNCT02346240Phase 3Results posted
• An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)CompletedNCT02326298Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)CompletedNCT02326272Phase 3Results posted
• Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque PsoriasisCompletedNCT00329303Phase 2Results posted
• Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/PhotochemotherapyCompletedNCT00245765Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06425549Phase 3
• A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical PracticeCompletedNCT04053881
• A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With PsoriasisCompletedNCT02529956Phase 1
• Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic SubjectCompletedNCT02303509Phase 1